Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip M Grant

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Plos One|July 10, 2010
Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infectionPhilip M Grant, Lauren Komarow, Janet Andersen, et al.
HIV Clinical Trials|December 17, 2013
Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202Philip M Grant, Camlin Tierney, Chakra Budhathoki, et al.
Viruses|March 28, 2024
Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping ReviewCarolyn Chu, Kaiming Tao, Vinie Kouamou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 15, 2013
Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiationPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
AIDS Research and Human Retroviruses|October 4, 2018
Effect of Testosterone Use on Bone Mineral Density in HIV-Infected MenPhilip M Grant, Xiuhong Li, Lisa P Jacobson, et al.
The Journal of Infectious Diseases|June 23, 2016
Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected IndividualsPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
The Journal of Infectious Diseases|September 25, 2012
Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164Philip M Grant, Lauren Komarow, Michael M Lederman, et al.
The Lancet. Gastroenterology & Hepatology|March 6, 2022
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trialNeil Gupta, Linda Manirambona, Fabienne Shumbusho, et al.
AIDS (London, England)|September 24, 2016
Long-term body composition changes in antiretroviral-treated HIV-infected individualsPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
The Lancet. Gastroenterology & Hepatology|March 6, 2022
Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trialFredrick Kateera, Fabienne Shumbusho, Linda Manirambona, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Plos One|July 10, 2010
Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infectionPhilip M Grant, Lauren Komarow, Janet Andersen, et al.
HIV Clinical Trials|December 17, 2013
Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202Philip M Grant, Camlin Tierney, Chakra Budhathoki, et al.
Viruses|March 28, 2024
Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping ReviewCarolyn Chu, Kaiming Tao, Vinie Kouamou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 15, 2013
Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiationPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
AIDS Research and Human Retroviruses|October 4, 2018
Effect of Testosterone Use on Bone Mineral Density in HIV-Infected MenPhilip M Grant, Xiuhong Li, Lisa P Jacobson, et al.
The Journal of Infectious Diseases|June 23, 2016
Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected IndividualsPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
The Journal of Infectious Diseases|September 25, 2012
Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164Philip M Grant, Lauren Komarow, Michael M Lederman, et al.
The Lancet. Gastroenterology & Hepatology|March 6, 2022
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trialNeil Gupta, Linda Manirambona, Fabienne Shumbusho, et al.
AIDS (London, England)|September 24, 2016
Long-term body composition changes in antiretroviral-treated HIV-infected individualsPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
The Lancet. Gastroenterology & Hepatology|March 6, 2022
Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trialFredrick Kateera, Fabienne Shumbusho, Linda Manirambona, et al.
Pageof 4